| pubmed-article:12034047 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0596972 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0032520 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C1521743 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0181904 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C1704646 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0728873 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0392762 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0681890 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C1442457 | lld:lifeskim |
| pubmed-article:12034047 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:12034047 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12034047 | pubmed:dateCreated | 2002-5-29 | lld:pubmed |
| pubmed-article:12034047 | pubmed:abstractText | The relation between the change in hepatitis C virus (HCV) RNA levels at the start of interferon-beta (IFN-beta) treatment and the long-term therapeutic response remains poorly defined. In 20 patients with chronic hepatitis C who received IFN-beta (total dose 126-756 MU), the changes in serum HCV RNA during the first 2 weeks of therapy were monitored by real-time quantitative polymerase chain reaction (PCR). The serum HCV RNA level decreased rapidly during the first 24 h of therapy (first phase) and more slowly thereafter (second phase), with a mean exponential decay rate of 1.17 log10/day and 0.37 log10/day, respectively. Three patients had a sustained virologic response, 10 patients had a transient response, and 7 patients had no response. The differences in the rate of first-phase viral decline among the three groups were not significant (p = 0.21), but the differences in the rate of second-phase viral decline were significant (p = 0.0021). The mean decay rate between the end of the first 24 h and day 14 was 0.96 +/- 0.43 log10/day in sustained responders, 0.39 +/- 0.30 log10/day in transient responders, and 0.13 +/- 0.09 log10/day in nonresponders. We conclude that during the first 2 weeks of therapy, changes in serum HCV RNA levels as monitored by real-time quantitative PCR can be used to predict the long-term response to treatment with IFN-beta. | lld:pubmed |
| pubmed-article:12034047 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12034047 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12034047 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12034047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12034047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12034047 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12034047 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12034047 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:12034047 | pubmed:issn | 1079-9907 | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:NishiguchiShu... | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:EnomotoMasaru... | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:ShiomiSusumuS | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:TanakaMotohar... | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:FukudaKatsuhi... | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:TamoriAkihiro... | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:HabuDaikiD | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:TakedaTadashi... | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:YanoYoshihisa... | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:OtaniShuzoS | lld:pubmed |
| pubmed-article:12034047 | pubmed:author | pubmed-author:UedaTadashiT | lld:pubmed |
| pubmed-article:12034047 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12034047 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:12034047 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12034047 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12034047 | pubmed:pagination | 389-95 | lld:pubmed |
| pubmed-article:12034047 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:meshHeading | pubmed-meshheading:12034047... | lld:pubmed |
| pubmed-article:12034047 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12034047 | pubmed:articleTitle | Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response. | lld:pubmed |
| pubmed-article:12034047 | pubmed:affiliation | Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan. | lld:pubmed |
| pubmed-article:12034047 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12034047 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12034047 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
